Today: 19 April 2026
DroneShield share price sinks after ASX cash-flow update; what to watch next for ASX:DRO
28 January 2026
1 min read

DroneShield share price sinks after ASX cash-flow update; what to watch next for ASX:DRO

Sydney, Jan 28, 2026, 17:26 AEDT — Market closed

  • DroneShield shares dropped as investors absorbed the latest quarterly cash-flow figures and new investor documents.
  • Traders are gauging the speed at which new orders turn into cash as the company approaches its full-year audit period.
  • Upcoming triggers for the stock are the release of the company’s audited FY2025 results and its reporting dates set for February.

Shares of Australia’s DroneShield Ltd dropped 5.5% to finish at A$3.95 on Wednesday, hitting a low of A$3.93 during the session. The move came as investors digested a late-January update on cash inflows and growth prospects.

The counter-drone equipment maker reported in its quarterly activities report and Appendix 4C cash flow statement for the three months ended Dec. 31 that customer revenue increased to A$51.3 million. Customer cash receipts also jumped, reaching A$63.5 million. Operating cash flow came in positive at A$7.7 million for the quarter and A$23.4 million over the past 12 months. At quarter-end, cash and cash equivalents stood at roughly A$210.4 million.

Why it matters now: the stock’s action has shifted, driven less by headline order wins and more by contract timing, deliveries, and cash conversion. The December-quarter figures remain unaudited, setting up the next audit as a key moment to see if margins and cash flow can sustain after a year of rapid expansion.

During the earnings call for the December quarter, CEO Oleg Vornik highlighted a surge in sales and receipts, saying the company had “started really strongly on the 2026.” Seeking Alpha

DroneShield highlighted several updates “during and subsequent to the quarter,” such as an AI software launch, the opening of a South Australia R&D facility, and multiple contracts—covering European military orders as well as deals across Latin America and Asia-Pacific.

The company’s investor presentation flagged a January 2026 sales pipeline of A$2.09 billion but cautioned these opportunities are “unweighted” and might not convert into actual sales. AFR Company Announcements

That caveat lies at the heart of the risk: defence and security contracts may be delayed, order volumes can shift, and turning the pipeline into actual revenue is often uneven. On top of that, a stronger Australian dollar can reduce the local-currency worth of international sales.

As the market stays closed, attention shifts to whether the pullback carries over into Thursday’s session and if the March-quarter delivery and cash receipt updates keep pace with those from December.

DroneShield’s next key date is Feb. 24, set for its annual and preliminary reporting updates, as listed on Market Index’s company calendar.

Stock Market Today

  • Nordea Bank Abp's Mixed Share Performance and Valuation Analysis
    April 18, 2026, 10:42 PM EDT. Nordea Bank Abp (HLSE:NDA FI) exhibits mixed returns with a negative year-to-date but a 51.1% total return over one year, showing strong long-term momentum. The bank's share price closed at €16.02, slightly below the €16.55 analyst target and a fair value estimate of €17.03, suggesting it may be undervalued. Nordea is investing heavily in digital technologies and cybersecurity, aiming to improve net margins and fee income. However, potential risks include Nordic housing market weakness and rising regulatory costs. Investors are advised to weigh both upside potential and downside risks before making decisions, considering broader financial sector comparisons and market conditions.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
UPS stock price swings as 30,000-job cut plan and 2026 outlook land after the bell
Previous Story

UPS stock price swings as 30,000-job cut plan and 2026 outlook land after the bell

Mineral Resources (ASX:MIN) share price slips after inflation shock as quarterly report looms
Next Story

Mineral Resources (ASX:MIN) share price slips after inflation shock as quarterly report looms

Go toTop